---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-007054"
form_type: "8-K"
ticker: "TCRT"
cik: "0001107421"
company_name: "Alaunos Therapeutics, Inc."
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:10:08.283777+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Alaunos reports positive preclinical obesity data but cash runway only through Q1 2026

## Summary
- Preclinical DIO mouse study shows statistically significant dose-related weight loss and improved body composition; lead compound identified.
- Cash and equivalents ~$1.9M as of Sep 30, 2025; runway only through Q1 2026; plans additional financing by end of Q1 2026.
- Shareholder group with 8.6% stake requests Gerald W. Bruce as director; Corporate Governance Committee to review.
- Terminated engagement with Cantor Fitzgerald as financial advisor; no fees paid, no strategic transaction consummated.
- Amended bylaws with stockholder nomination advance notice requirements and universal proxy rule compliance.

## SEC filing metadata
- accession: 0001193125-26-007054
- form_type: 8-K
- ticker: TCRT
- cik: 0001107421
- company_name: Alaunos Therapeutics, Inc.
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.02, 3.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1107421/000119312526007054/0001193125-26-007054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1107421/000119312526007054/tcrt-20260108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-007054
- JSON: https://secwatch.observer/filing/0001193125-26-007054.json
- Plain text: https://secwatch.observer/filing/0001193125-26-007054.txt

## Key facts
- Material Agreements
  Alaunos Therapeutics, Inc. terminated Engagement Letter dated August 14, 2023 with Cantor Fitzgerald & Co. valued at Termination of engagement letter for strategic transactions advisory; no fees payable upon terminati (effective 2026-01-08).
  - Action: termination
  - Counterparty: Cantor Fitzgerald & Co.
  - Value: Termination of engagement letter for strategic transactions advisory; no fees payable upon terminati
  - Effective: 2026-01-08
  source text: On January 8, 2026, the Company delivered written notice to Cantor Fitzgerald & Co. (“Cantor”) terminating, effective immediately, the engagement letter dated August 14, 2023 (the “Engagement Letter”), pursuant to which Cantor had been engaged as the Company’s exclusive financial advisor in connection with the exploration of potential strategic transactions.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1107421/000119312526007054/0001193125-26-007054-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.